These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 15211328)
21. Effects of niacin and chromium on the expression of ATP-binding cassette transporter A1 and apolipoprotein A-1 genes in HepG2 cells. Siripurkpong P; Na-Bangchang K J Nutr Biochem; 2009 Apr; 20(4):261-8. PubMed ID: 18602814 [TBL] [Abstract][Full Text] [Related]
23. Emerging strategies for increasing high-density lipoprotein. Forrester JS; Shah PK Am J Cardiol; 2006 Dec; 98(11):1542-9. PubMed ID: 17126667 [TBL] [Abstract][Full Text] [Related]
24. Pathways for oxidation of high-density lipoprotein in human cardiovascular disease. Shao B; Oda MN; Vaisar T; Oram JF; Heinecke JW Curr Opin Mol Ther; 2006 Jun; 8(3):198-205. PubMed ID: 16774039 [TBL] [Abstract][Full Text] [Related]
25. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Terasaka N; Wang N; Yvan-Charvet L; Tall AR Proc Natl Acad Sci U S A; 2007 Sep; 104(38):15093-8. PubMed ID: 17846428 [TBL] [Abstract][Full Text] [Related]
26. Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity. Berrougui H; Khalil A Rejuvenation Res; 2009 Apr; 12(2):117-26. PubMed ID: 19405812 [TBL] [Abstract][Full Text] [Related]
27. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Liao D; Tan H; Hui R; Li Z; Jiang X; Gaubatz J; Yang F; Durante W; Chan L; Schafer AI; Pownall HJ; Yang X; Wang H Circ Res; 2006 Sep; 99(6):598-606. PubMed ID: 16931800 [TBL] [Abstract][Full Text] [Related]
28. Hydrogen Activates ATP-Binding Cassette Transporter A1-Dependent Efflux Ex Vivo and Improves High-Density Lipoprotein Function in Patients With Hypercholesterolemia: A Double-Blinded, Randomized, and Placebo-Controlled Trial. Song G; Lin Q; Zhao H; Liu M; Ye F; Sun Y; Yu Y; Guo S; Jiao P; Wu Y; Ding G; Xiao Q; Qin S J Clin Endocrinol Metab; 2015 Jul; 100(7):2724-33. PubMed ID: 25978109 [TBL] [Abstract][Full Text] [Related]
30. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
31. Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein. Niesor EJ; Schwartz GG; Perez A; Stauffer A; Durrwell A; Bucklar-Suchankova G; Benghozi R; Abt M; Kallend D Cardiovasc Drugs Ther; 2015 Feb; 29(1):7-14. PubMed ID: 25749868 [TBL] [Abstract][Full Text] [Related]
32. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice. Tiniakou I; Kanaki Z; Georgopoulos S; Chroni A; Van Eck M; Fotakis P; Zannis VI; Kardassis D Atherosclerosis; 2015 Nov; 243(1):77-85. PubMed ID: 26363436 [TBL] [Abstract][Full Text] [Related]
33. Statins and metabolism of high density lipoprotein. Sviridov D; Nestel P; Watts G Cardiovasc Hematol Agents Med Chem; 2007 Jul; 5(3):215-21. PubMed ID: 17630948 [TBL] [Abstract][Full Text] [Related]
34. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. Ohashi R; Mu H; Wang X; Yao Q; Chen C QJM; 2005 Dec; 98(12):845-56. PubMed ID: 16258026 [TBL] [Abstract][Full Text] [Related]
37. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Ou J; Wang J; Xu H; Ou Z; Sorci-Thomas MG; Jones DW; Signorino P; Densmore JC; Kaul S; Oldham KT; Pritchard KA Circ Res; 2005 Nov; 97(11):1190-7. PubMed ID: 16224061 [TBL] [Abstract][Full Text] [Related]
39. Functionality of High-Density Lipoprotein as Antiatherosclerotic Therapeutic Target. Hoekstra M; Van Berkel TJ Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):e87-e94. PubMed ID: 27784702 [No Abstract] [Full Text] [Related]
40. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. Zheng L; Nukuna B; Brennan ML; Sun M; Goormastic M; Settle M; Schmitt D; Fu X; Thomson L; Fox PL; Ischiropoulos H; Smith JD; Kinter M; Hazen SL J Clin Invest; 2004 Aug; 114(4):529-41. PubMed ID: 15314690 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]